Advertisement
Loading...

Healios K.K.

HLOSFPNK
Healthcare
Biotechnology
$2.20
$0.00(0.00%)
U.S. Market is Open • 15:53

Healios K.K. Fundamental Analysis

Healios K.K. (HLOSF) shows weak financial fundamentals with a PE ratio of -13.99, profit margin of -42.32%, and ROE of -75.26%. The company generates $0.1B in annual revenue with weak year-over-year growth of -81.43%.

Key Strengths

Cash Position3951.81%
PEG Ratio-0.00
Current Ratio2.05

Areas of Concern

ROE-75.26%
Operating Margin-51.16%
We analyze HLOSF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -3350.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-3350.4/100

We analyze HLOSF's fundamental strength across five key dimensions:

Efficiency Score

Weak

HLOSF struggles to generate sufficient returns from assets.

ROA > 10%
-13.31%

Valuation Score

Excellent

HLOSF trades at attractive valuation levels.

PE < 25
-13.99
PEG Ratio < 2
-0.00

Growth Score

Moderate

HLOSF shows steady but slowing expansion.

Revenue Growth > 5%
-81.43%
EPS Growth > 10%
56.99%

Financial Health Score

Excellent

HLOSF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.34
Current Ratio > 1
2.05

Profitability Score

Weak

HLOSF struggles to sustain strong margins.

ROE > 15%
-7526.36%
Net Margin ≥ 15%
-42.32%
Positive Free Cash Flow
No

Key Financial Metrics

Is HLOSF Expensive or Cheap?

P/E Ratio

HLOSF trades at -13.99 times earnings. This suggests potential undervaluation.

-13.99

PEG Ratio

When adjusting for growth, HLOSF's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values Healios K.K. at 5.80 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

5.80

EV/EBITDA

Enterprise value stands at -21.52 times EBITDA. This is generally considered low.

-21.52

How Well Does HLOSF Make Money?

Net Profit Margin

For every $100 in sales, Healios K.K. keeps $-42.32 as profit after all expenses.

-42.32%

Operating Margin

Core operations generate -51.16 in profit for every $100 in revenue, before interest and taxes.

-51.16%

ROE

Management delivers $-75.26 in profit for every $100 of shareholder equity.

-75.26%

ROA

Healios K.K. generates $-13.31 in profit for every $100 in assets, demonstrating efficient asset deployment.

-13.31%

Following the Money - Real Cash Generation

Operating Cash Flow

Healios K.K. generates limited operating cash flow of $-3.16B, signaling weaker underlying cash strength.

$-3.16B

Free Cash Flow

Healios K.K. generates weak or negative free cash flow of $-3.33B, restricting financial flexibility.

$-3.33B

FCF Per Share

Each share generates $-30.89 in free cash annually.

$-30.89

FCF Yield

HLOSF converts -10.32% of its market value into free cash.

-10.32%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-13.99

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

5.80

vs 25 benchmark

P/S Ratio

Price to sales ratio

506.65

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.34

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.05

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.75

vs 25 benchmark

ROA

Return on assets percentage

-0.13

vs 25 benchmark

ROCE

Return on capital employed

-0.21

vs 25 benchmark

How HLOSF Stacks Against Its Sector Peers

MetricHLOSF ValueSector AveragePerformance
P/E Ratio-13.9928.65 Better (Cheaper)
ROE-75.26%795.00% Weak
Net Margin-4231.89%-49787.00% (disorted) Weak
Debt/Equity0.340.40 Neutral
Current Ratio2.053.73 Strong Liquidity
ROA-13.31%-20255.00% (disorted) Weak

HLOSF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Healios K.K.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

83.98%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

80.79%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

61.68%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ